Status report on the atopic dermatitis registry TREATgermany

Doreen Siegels¹,a, Eva Haufe¹, Luise Heinrich¹, Thomas Werfel²,b, Stephan Weidinger³,c, Jochen Schmitt¹,d; and the TREATgermany Study Group

¹Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, ²Department of Immunodermatology and Experimental Allergology, Department of Dermatology, Allergology and Venereology, Hannover Medical School, Hannover, and ³Department of Dermatology, Venereology and Allergology, Schleswig-Holstein University Hospital, Kiel Campus, Kiel, Germany

Abstract. Background: The TREATgermany registry collects data from children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) in Germany. For this purpose, clinical and patient-reported outcomes, the course of the disease, and applied therapies are observed. Methods: TREATgermany recruits patients with moderate-to-severe AD according to the diagnostic criteria of the UK Working Party, an “Objective Scoring for Atopic Dermatitis” (oSCORAD) > 20 and/or currently antiinflammatory systemic treatment for AD or previous antiinflammatory systemic treatment for AD within past 24 months before inclusion. No study related interventions will be performed. Currently, 59 dermatological practices, clinics, and university hospitals are participating in TREATgermany (as of May 2021). Based on the interim analysis of October 13, 2020, patient characteristics were described from 4,373 documented visits of adult participants (n = 1,025). Results: The mean age at inclusion in TREATgermany was 42 years, 57.7% of patients were men (n = 591) and 42.3% were women (n = 434). According to oSCORAD, 85.8% of those included suffered from moderate-to-severe AD. At baseline visit, 744 patients had already received one or more systemic treatments for AD (glucocorticosteroids n = 600, ciclosporin A (CSA) n = 307, dupilumab n = 98). 597 patients received dupilumab during their participation in TREATgermany, 134 patients received CSA. Conclusion: With the increasing number of recruitment centers (October 2020: 38 centers; May 2021: 59 centers), TREATgermany can continue to make an important contribution to health services research for patients with moderate-to-severe AD. The registry fulfills the methodological requirements of IQWiG for the collection and processing of healthcare-related data. With the successful and expected approval of further systemic treatments, these can be compared in terms of efficacy and safety in the future. In addition, with the recruitment of children and adolescents started in 2021, this patient group can also be observed.

Introduction

Atopic dermatitis (AD, synonym: atopic eczema) is a chronic inflammatory, often episodic dermatosis affecting ~ 8% of adults and ~ 7% of children and adolescents in Germany [1, 2, 3]. A previous multinational epidemiological study in adults reported a cross-national prevalence of 2.1 – 4.9% [1]. In order to monitor moderately to severely affected children, adolescents, and adults with AD in Germany with regard to the clinical and subjective course of the disease as well as the course of therapy, the German registry TREATgermany collects comprehensive parameters for disease monitoring.

In 2016, TREATgermany emerged from TREATeczema and today represents a high-quality national registry that fulfills all quality criteria and methodological requirements for clinical registries as described in the Memorandum Register for Health Services Research [4] and in the criteria of the Institute for Quality and Efficiency in Health Care (IQWiG, Rapid Report) [5].

Starting in 2016, adult patients have been observed in TREATgermany and, since January 2021, children and adolescents have
also been recruited. The study design of a non-interventional, prospective cohort study collects data from routine health care data. The detailed description of the registry, including the variables collected, the baseline characteristics of the first 612 adult patients, and analyses of reduced quality of life have been reported previously [6, 7].
In the following, we report the current status and results of the October 2020 interim data analysis of the TREATgermany registry.

Materials and methods

TREATgermany recruits patients with moderate-to-severe AD according to the diagnostic criteria of the UK Working Party [8], i.e., an oSCORAD (“Objective Scoring for Atopic Dermatitis”) [9] > 20 [10] and/or an systemic therapy for AD within the past 24 months before inclusion in the registry. No study related interventions will be performed. Included patients will be followed up prospectively for at least 24 months. During the follow-up period, standardized study visits will be conducted to prospectively document patient characteristics, clinical data and symptomatology, patient-reported or subjective disease severity, clinical reasons for treatment decisions, and treatment satisfaction.

Currently, 59 dermatological practices, clinics, and university hospitals are participating in TREATgermany (Table 1).

The main objectives of TREATgermany are:

- To provide a platform, network, and other resources for basic molecular research and embedded randomized clinical trials.

In accordance with the recommended Core Outcome Set (COS) of the Harmonizing Outcome Measures for Eczema Initiative (HOME Initiative) [11, 12, 13], the target parameters for evaluating the effectiveness of treatments for AD include:

- clinical symptom severity (“Eczema Area and Severity Index” score (EASI) [14], oSCORAD)
- subjective symptom severity (“Patient-Oriented Eczema Measure” (POEM) [15, 16], itching and sleep disturbances)
- disease episodes (total number/well-controlled weeks)
- and quality of life (“Dermatological Quality of Life Index” (DLQI) [17, 18]).

Furthermore, side effects, adverse events and reasons for treatment discontinuation are documented by the recruiting centers. Patient and physician satisfaction with treatment and reasons for choosing certain interventions are assessed.

Data collection is conducted in an online database and electronic patient questionnaires.

The TREATgermany research project was submitted to all relevant ethics committees and received a positive vote (No. EK TUD 118032016). TREATgermany is registered in the clinicaltrials.gov database (NCT03057860) and the ENCePP Resource Database (EMA).
Results

TREATgermany has included 1,180 adults and 99 children or adolescents in the registry by May 2021 (Figures 1, 2).

The following data descriptions are based on the October 13, 2020, interim analysis and refer to 1,025 enrolled adult patients with 4,373 documented visits from 38 recruitment centers at that time.

Characteristics of the included patients

The mean age at inclusion in the registry was 42 years, 57.7% of patients were men (n = 591), and 42.3% were women (n = 434). According to oSCORAD, 85.8% of the included patients were moderately to severely affected by AD. More than half of the patients were affected on the face (78.0%), hands (74.6%), large joint flexures (76.1%), or neck (78.0%).

The majority of patients stated that they lived in a partnership. 77.6% of patients were
employed, and of these 73.2% in full-time. 50.9% reported that they had not previously smoked. At the baseline visit, patients were also asked about their medical history regarding AD. 57.0% of registry patients stated that they had AD since infancy. 13.9% and 10.7%, reported onset of AD before/at school age. 52.5% of patients being employed reported sickness absence caused by AD in the year before enrollment for registry (median: 14 days/year). 43.6% and 23.8% of patients reported hospitalization and rehabilitation due to AD in the 5 years prior to inclusion.

65.9% of patients also reported that their skin was permanently affected by AD in the year prior to inclusion. The remaining 34.1% of patients were affected by AD for an average of 6 months (6.3 ± 3.2) of the past year. The percentage of body surface area (BSA) affected within the last 3 days before the visit was 19.0% on average (19.0 ± 22.5, median = 11), according to the patients’ assessment.

Regarding their concomitant diseases, 17.9% and 17.8% of the patients stated that they had suffered from allergic rhinitis and allergic asthma, in the past. Another 52.1% and 33.4% of the patients reported corresponding symptoms in the past year. In summary, 70.0% and 51.2% of patients reported suffering from allergic rhinitis and allergic asthma.

At the baseline visit, ~40% of patients reported that their AD was severe or very severe. More than half experienced an extremely or very large effect on their quality of life (according to DLQI). The POEM sum score as a subjective reflection of disease severity is consistent with this finding. In contrast, ~60% of patients with AD did not experienced increased fatigue. The same percentage reported no or only mild symptoms of depression. Nevertheless, ~40% of those affected by AD showed fatigue and depressive symptoms.

The detailed baseline characteristics of the 1,025 patients and their clinical and subjective symptom severity are shown in Tables 2, 3, and 4.

The most frequently reported subjective symptoms of AD were pruritis, pain, and sleep disturbance. Using 11-point Likert scales (0 = no symptom to 10 = most severe symptoms imaginable), patients rated pruritus as the most severe (mean 5.7), followed by sleep disturbance (mean 4.5) and pain (mean 3.7).

Patients perceived their AD as well controlled for an average of 4.4 (4.4 ± 3.8) weeks of the past 12 weeks. The mean num-
Number of weeks perceived as fully controlled was 2 weeks (2.0 ± 3.4). The percentage of patients reporting no weeks without (fully controlled) symptoms within the last 12 weeks was 57.7%.

### Systemic therapy of TREATgermany patients

At the time of inclusion in TREATgermany, 600 patients had already received systemic therapy with glucocorticosteroids, 307 with ciclosporin A, 45 with methotrexate, 28 with azathioprine, and 98 with dupilumab in the course of their disease history. Lower numbers of cases were documented for mycophenolates, alitretinoin, JAK inhibitors, and other systemic treatments (Table 5).

91.3% (n = 927) of patients received topical glucocorticosteroids, and 38.0% (n = 381) received UV therapy in the 12 months before inclusion in the registry. Based on the data from October 2020 including all follow-up visits, 597 patients received systemic therapy with dupilumab during their participation in TREATgermany, 442 had this therapy initiated during their participation in the registry (40 of them outside registry visits). 134 patients received systemic therapy with ciclosporin A during their participation in TREATgermany.

The subgroup of patients who received dupilumab therapy showed a better improvement of the symptoms compared to patients who did not receive systemic therapy. The mean oSCORAD for dupilumab patients at the 3rd follow-up visit was 19.9 (SD 9.9) and for patients not receiving systemic therapy was 27.7 (SD 13.6). The EASI score showed the same trend (dupilumab mean 4.1 (SD 4.4) vs. no systemic therapy mean 7.0 (SD 7.0)). The results of subjective symptom severity, measured by POEM score, pain, pruritus and sleep disturbance, disease relapses, and Patient Global Assessment (PGA), also showed a greater improvement for the dupilumab patients. These comparative follow-up studies were performed only for individuals who were initiated on dupilumab during their participation in TREATgermany and who had at least three documented follow-up visits (n = 224, including at least one follow-up visit with dupilumab therapy). Patients who were

| Baseline characteristics | Number of patients |
|--------------------------|--------------------|
| **Sex**                  |                    |
| Male                     | 591 (57.7%)        |
| Female                   | 434 (42.3%)        |
| **Age, mean (SD)**       | 41.7 (14.6) (n = 1,025) |
| **BMI, mean (SD)**       | 25.9 (5.4) (n = 1,009) |
| **Marital status**       |                    |
| Solid partnership, unmarried | 265 (26.2%)    |
| Married                  | 391 (38.6%)        |
| Divorced                 | 42 (4.2%)          |
| Widowed                  | 11 (1.1%)          |
| Single                   | 303 (29.9%)        |
| **Education level**      |                    |
| Without school-leaving qualification | 8 (0.8%) |
| Lower secondary school graduates | 124 (12.2%) |
| Secondary school diploma | 377 (37.2%)        |
| High school diploma      | 259 (25.5%)        |
| University degree        | 246 (24.3%)        |
| **Gainful employment**   |                    |
| Not employed             | 227 (22.4%)        |
| Employed                 | 788 (77.6%)        |
| **Employment status**    |                    |
| Full-time (35 hours and more) | 574 (73.2%)    |
| Part time or hourly      | 172 (21.9%)        |
| Leave of absence (parental leave or similar) | 8 (1.0%) |
| Trainee, re-trainee      | 30 (3.8%)          |
| **Non-employed persons** |                    |
| Pensioner/retiree in early retirement | 71 (32.0%) |
| Househusband/Housewife   | 24 (10.8%)         |
| Pupil/student            | 67 (30.2%)         |
| Unemployed               | 46 (20.7%)         |
| Early retiree            | 14 (6.3%)          |
| **Smoker status**        |                    |
| Smoker                   | 246 (24.2%)        |
| Ex-smoker (<10 years not smoked) | 143 (14.1%)   |
| Ex-smoker (≥ 10 years not smoked) | 109 (10.7%)   |
| Never smoked             | 517 (50.9%)        |
| **Allergic comorbidities** |                |
| Allergic rhinoconjunctivitis (hay fever) | 650 (65.9%) |
| Bronchial asthma          | 443 (44.3%)        |
| **Other comorbidities**  |                    |
| Arterial hypertension    | 189 (18.8%)        |
| Heart failure (≥ NYHA III) | 5 (0.5%)         |
| Previous myocardial infarction (queried since 2018) | 7 (0.9%) |
| Previous Applex (queried since 2018) | 4 (0.5%) |
| Diabetes mellitus type 1  | 1 (0.1%)           |
| Diabetes mellitus type 2  | 36 (3.5%)          |
| Crohn’s disease/Colitis ulcerosa | 12 (1.2%) |
| Renal failure            | 11 (1.1%)          |
| Rheumatoid arthritis     | 3 (0.3%)           |
| Depression               | 97 (9.7%)          |
| Cancers (queried since 2018) | 16 (2.0%)      |

SD = standard deviation.
not prescribed systemic therapy either at enrollment or at the first three follow-up visits were selected as the comparison group (n = 129).

### Adverse events

Adverse events occurred in 246 registry patients (24%) in 407 visits, with 462 individual adverse events documented. The most frequently mentioned adverse event was

| Subjective symptom severity | Number of patients |
|-----------------------------|--------------------|
| PGA                         |                    |
| Clear                       | 26 (2.6%)          |
| Almost clear                | 81 (8.0%)          |
| Mild                        | 207 (20.5%)        |
| Moderate                    | 299 (29.5%)        |
| Severe                      | 287 (28.4%)        |
| Very severe                 | 112 (11.1%)        |
| DLQI                        |                    |
| DLQI, mean (SD)             | 11.8 (7.8)         |
| (n = 1,012)                 |                    |
| DLQI – Categories           |                    |
| No effect at all on patient’s life (0 – 1) | 85 (8.4%) |
| Small effect on patient’s life (2 – 5) | 179 (17.7%) |
| Moderate effect on patient’s life (6 – 10) | 232 (23.9%) |
| Very large effect on patient’s life (11 – 20) | 356 (35.2%) |
| Extremely large effect on patient’s life (21 – 30) | 160 (15.8%) |
| POEM                        |                    |
| POEM, mean (SD)             | 16.8 (7.6)         |
| (n = 1,014)                 |                    |
| POEM – Categories           |                    |
| Clear or almost clear (0 – 2) | 50 (4.9%)         |
| Mild (3 – 7)                | 93 (9.2%)          |
| Moderate (8 – 16)           | 316 (31.2%)        |
| Severe (17 – 24)            | 375 (37.0%)        |
| Very severe (25 – 28)       | 180 (17.8%)        |
| Fatigue, mean (SD)          | 3.7 (1.6)          |
| (n = 1,011)                 |                    |
| Fatigue – Categories        |                    |
| Normal (FSS ≤ 4)            | 613 (60.6%)        |
| Increased (FSS > 4 and ≤ 5) | 163 (16.1%)        |
| High (FSS > 5)              | 235 (23.2%)        |
| CESD-D                      |                    |
| CESD-D, mean (SD)           | 14.9 (10.1)        |
| (n = 1,014)                 |                    |
| CESD-D – Categories         |                    |
| No to mild depressive symptoms (0 to < 16) | 616 (60.7%) |
| Moderate depressive symptoms (≥ 16 to < 24) | 208 (20.5%) |
| Major depressive symptoms (≥ 24) | 190 (18.7%) |

SD = standard deviation.
conjunctivitis (n = 227; of which n = 222 in patients with dupilumab therapy), as well as skin disorders (n = 24), headache (n = 20), herpes disorders (n = 19), eye disorders (not conjunctivitis, n = 19), and gastrointestinal complaints (n = 18). All other adverse events occurred less frequently (n ≤ 15) (Table 6).

**Discussion**

As a prospective cohort study, TREATgermany makes an important contribution to health services research on the treatment of AD in Germany. In addition, TREATgermany is part of the European registry family TREAT [19], which should enable the pooling of data for safety and efficacy analyses from different European countries in the future.

The reported interim analysis of the patients of the TREATgermany registry of October 13, 2020 characterized the 1,025 adults enrolled in the registry up to that date with regard to demographic values, previous diseases, clinical disease severity, the subjective disease severity of the patients, the applied systemic and concomitant therapies (e.g., topical therapies).

The population under consideration consisted of slightly more men (57.7%) than women (42.3%) and was on average 42 years old. More than half of the patients lived in a stable partnership (married and unmarried, 64.8%), ~ 50% had a high level of education.
(high school diploma, vocational diploma, or university degree), and 73.2% were employed full-time. The observed registry patients were affected by the comorbidities associated with AD [2] – allergic rhinoconjunctivitis and bronchial asthma (65.9% and 44.3%). Other common comorbidities were arterial hypertension (18.8%) and depression (9.7%). The association of AD and depression is in line with previous research findings and higher than in the general population of Germany (9.7 vs. 7.7%) [20, 21]. The association between AD and other autoimmune diseases reported in the literature [22] could not be observed in the previous data of the TREATgermany registry population.

In terms of clinical symptom severity, the adult patients were predominantly moderately to severely affected by AD (oSCORAD 85.8%, EASI score 76.8%). Face, hands, and the large joints were affected in more than 70%. The patients themselves rated their symptom severity similarly severe (POEM sum score 86.0%). Consequently, more than half also experienced a severe or very severe limitation with regard to their quality of life (DLQI 51.0%). The results regarding subjective symptom severity and impaired quality of life are consistent with previous scientific findings [23]. The percentage of patients with moderate AD (Investigator Global Assessment (IGA) 21.9% for the categories clear/almost clear/mild) can be explained by the fact that patients with ongoing or previous systemic therapy could also be included in the registry.

According to the inclusion criteria for TREATgermany, a high proportion of patients (n = 744) already received systemic therapy. Based on the data from October 2020, 597 patients received systemic therapy with dupilumab during their participation in the registry, 442 were prescribed this therapy during their participation in the registry. This high proportion is due to the limited treatment options available at that time. The subgroup of patients receiving dupilumab therapy showed a better clinical and subjective response compared to patients who did not receive systemic therapy.

**Conclusion and outlook**

With the increasing number of recruitment centers (October 2020: 38 centers, May 2021: 59 centers), TREATgermany can continue to make an important contribution to health services research for patients with moderate-to-severe AD and fulfills the methodological requirements of IQWiG for the collection and processing of health services-related data [5]. In addition to the description of various parameters from the perspective of clinicians and patients, a comprehensive picture of the current health care situation in Germany can be obtained through the recruitment from dermatological practices, clinics, and university hospitals. With the successful and expected approval of further systemic therapies since October 2020 (for example baricitinib [24, 25, 26], tralokinumab [27, 28], upadacitinib [29, 30]), further reports from the TREATgermany registry can also analyze interesting comparisons regarding clinical and subjective parameters, investigate the occurrence of side effects and compare them for different therapy options.

In January 2021, the registry was expanded to include children and adolescents. Until June 2021, 18 centers have been initiated and 99 children and adolescents have been included. A special feature of the survey of subjective symptom severity by the patients is the linguistic adaptation of various standardized questionnaires according to the age of the children and adolescents. First results for children and adolescents suffering from moderate-to-severe AD will be reported in 2022.

The collection of routine health care data through the TREATgermany registry and the expansion to all age groups will provide a better understanding of moderate-to-severe AD to all those involved in treatment and to those affected. All dermatology clinics, outpatient dermatologists, and general practitioners with a focus on AD in Germany are invited to participate as recruitment centers.
Acknowledgment

The TREATgermany study group consists of the centers named in the list of authors and the following recruiting centers:

– S. Abraham: Clinic and Polyclinic for Dermatology, Carl Gustav Carus University Hospital and Medical Faculty at the Technical University of Dresden.
– M. Asefi: Dermatological Study Center Hunsrück, Simmern.
– A. Asmussen: Practice Andrea Asmussen, MD, dermatology at the Lesum, Bremen.
– M. Augustin: Institute for Health Services Research in Dermatology and Nursing Professions, University Medical Center Hamburg-Eppendorf.
– M. Bell: Practice Magnus Bell, MD, Andernach.
– T. Bieber: Clinic and Polyclinic for Dermatology and Allergology, University Hospital Bonn.
– T. Biedermann: Clinic for Dermatology and Allergology, Klinikum rechts der Isar, Technical University of Munich.
– U. Boashi: Dermatology practice Ute Boashie, MD, Dresden.
– JJ. Brücher: Dermatology Outpatient Clinic Magdeburg.
– P. Buck: Practice Phillipp Buck, MD, Goldbek Medical Dermatology, Hamburg.
– R. Döllmann: Pediatric practice Dr. med. Robert Döllmann, Dresden.
– I. Effendy: Department of Dermatology, Rosenhöhe Clinic, Bielefeld.
– K. Ernter: Practice Dr. med. Konstantin Ernter, Nuremberg.
– K. Gardlo: Joint practice Dr. med. Kerstin Gardlo/Dr. med. Anette Jovic-Paris, Bad Neuenahr.
– B. Gerlach: Practice Dr. med. Beatrice Gerlach, Dresden.
– H. Gorriaahn-Maiterth: Dermasana Practice, Karlsruhe.
– B. Großmann: Dermatology practice of Dr. Bernd Großmann, Koblenz.
– E. Hamelmann: Clinic for Pediatric and Adolescent Medicine, Evangelisches Klinikum Bethel, Bielefeld.
– C. Handrick: Practice Christiane Handrick, MD, Berlin.
– U. Heimann: Dermatology practice Ulrike Heimann, Papenburg-Aschendorf.
– P. Höger: Pediatrics and Pediatric Dermatology/Allergology, Kath. Kinderkrankenhaus Wilhelmstift, Hamburg.
– M. Hoffmann: Practice Dr. med. Matthias Hoffmann, Witten.
– B. Homey: Clinic for Dermatology, University Hospital Düsseldorf.
– S. Kerzel: Barmherzige Brüder Hospital Regensburg, WECARE Study Center, KUNO Clinic St. Hedwig, Regensburg.
– R. von Kiedrowski: CMSS – Company for Medical Study and Service, Selters/Westerwald.
– A. Kleinheinz: Clinic for Dermatology, Allergology Outpatient Clinic, Elbe Klinikum Buxtehude.
– S. Lau: Section Pediatric Pneumology/Allergology/Endoscopy, Charité Universitätsmedizin Berlin.
– M. Mempel: Dermatology practice Prof. Dr. med. Martin Mempel, Elchmorn.
– K. Nemat: Practice for Pediatric Pneumology and Allergology, Children’s Center Dresden-Friedrichstadt.
– K. Neubert: Practice Dipl.-Med. Kathrin Neubert, Burgstädt.
– I. Neustädter: Cnopfsche Kinderklinik/Neonatologie, Pädiatrie, DIAKONEO KdöR, Nuremberg.
– H. Ott: Pediatric Dermatology and Allergology, Kinder- und Jugendkrankenhaus auf der Bult, Hannover.
– M. Pawlak: Practice Dr. med. Anika Hünemund and Mario Pawlak, Heilbad Heiligenstadt.
– A. Pinter: Department of Dermatology, Venereology and Allergology, Clinical Research, University Hospital Frankfurt am Main.
– I. Reitenbach-Blindt: Dermasana practice, Eggenstein-Leopoldshafen.
– J. Rossbacher: Practice Jens Rossbacher/Dr. med. Klaus Spickermann, Hautzentrum Friedrichshain, Berlin.
– R. Salgo: Pediatric Dermatology Practice Dr. med. Rebekka Salgo, Frankfurt am Main.
– T. Schaefer: Practice Dr. med. Thomas Schaefer/Dr. med. Doreen Belz, Derma Cologne.
– K. Schäkel: University Department of Dermatology, Heidelberg University Hospital.
Funding

TREAT Germany is an academic, investigator-initiated clinical registry financially supported by Sanofi-Aventis Deutschland GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, and Abbvie.

Conflicts of interest

TW is Co-Principal Investigator of the German Atopic Dermatitis Registry TREAT-germany. TW has received honoraria for lectures or scientific advice on atopic dermatitis from AbbVie, Almirall, Galderma, Jans-sen/JNJ, Leo Pharma, Leti, Lilly, Novartis, Pfizer, and Regeneron/Sanofi.

SW is Co-Principal Investigator of the German Atopic Dermatitis Registry TREAT-germany. SW has received institutional research grants from Novartis, L’Oreal, and La Roche Posay; he has performed consulting work for Sanofi-Genzyme, Regeneron, LEO Pharma, Eli Lilly, AbbVie, Pfizer, GSK, and Kymab; he has also lectured at educational events sponsored by Sanofi-Genzyme, Regeneron, LEO Pharma, Eli Lilly, AbbVie, and Pfizer; and received travel grants from Sanofi-Genzyme, Regeneron, LEO Pharma, Eli Lilly, AbbVie, and Pfizer.

JS is leading Principal Investigator of the German Atopic Dermatitis Registry TREAT-germany. JS has received institutional grants from Novartis and Pfizer for scientifically initiated research and honoraria for consulting from Sanofi, Lilly, Novartis, and ALK.

All other authors declare no conflict of interest.

References

[1] Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, Margolis DJ, de Bruin-Weller M, Eckert L. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018; 73: 1284-1293. CrossRef PubMed

[2] Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019; 123: 144-151. CrossRef PubMed

[3] Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, Rossi AB, Brignoli L, Saba G, Guillemin I, Fenton MC, Auziere S, Eckert L. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021; 126: 417-428.e2. CrossRef PubMed

[4] Stausberg J, Maier B, Bestehorn K, Gothe H, Groene O, Jacke C, Jänicke M, Kostuj T, Mathes T, Niemeyer A, Oßbrich K, Schmitt J, Neugebauer E. [Memorandum Registry for Health Services Research: Update 2019]. Gesundheitswesen. 2020; 82: e39-e66. PubMed

[5] IQWiG Reports – Commission No. A19-43 (2020). Concepts for the generation of routine practice
data and their analysis for the benefit assessment of drugs according to §35a Social Code Book V (SGB V).

[6] Hanifin J, Abraham S, Heratizadeh A, Harder I, Zink A, Weisshaar E, Kleinheinz A, von Kiedrowski R, Worm M, Bell M, Wollenberg A, Neuert K, Staubach-Renz P, Hilgers M, Bieber T, Fell I, Homey B, Effendy I, Mempel M, Schäkel K et al. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema: Results from the German atopic eczema registry TREATgermany]. Hautarzt. 2018; 69: 815-824. CrossRef PubMed

[7] Heratizadeh A, Hanif J, Stölzel D, Abraham S, Heinrich L, Kleinheinz A, Wollenberg A, Weisshaar E, Augustin M, Wiemers F, Zink A, von Kiedrowski R, Hilgers M, Worm M, Pavlak M, Stericher L, Fell I, Hartick C, Schäkel K, Staubach-Renz P, et al; TREATgermany Study Group. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol. 2020; 34: 1263-1272. CrossRef PubMed

[8] Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, Bingham EA, Finlay AY, Pembroke AC, Graham-Brown RA, et al. The U.K. Working Party’s diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994; 131: 383-396. CrossRef PubMed

[9] Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993; 186: 23-31. CrossRef PubMed

[10] Kunz B, Oranje AF, Løhrze L, Starlzer JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997; 195: 10-19. CrossRef PubMed

[11] Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Farue M, Chalmers J, Williams HC. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol. 2015; 135: 24-30. CrossRef PubMed

[12] Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P. Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013; 132: 1337-1347. CrossRef PubMed

[13] Schmitt J, Langan S, Stamm T, Williams HC; Harmonizing Outcome Measurements in Eczema (HOME) Delphi panel. Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol. 2011; 131: 623-630. CrossRef PubMed

[14] Hanifin JM, Burton J, O’toole M, Chernoff R, Tofte SJ, Graeber M, Evaluator Group; EAASI. Evaluator Group. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001; 10: 11-18. CrossRef PubMed

[15] Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013; 169: 1326-1332. CrossRef PubMed

[16] Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004; 140: 1513-1519. CrossRef PubMed

[17] Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19: 210-216. CrossRef PubMed

[18] Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004; 9: 169-180. CrossRef PubMed

[19] Spuls PI, Gerber LA, Apfelbacher CJ, Wall D, Arents BWM, Barbarot S, Roberts A, Deleuran M, Middelkamp-Hup MA, Versgaard C, Weidinger S, Schmitt J, Irvine AD, Sloh C. The International TREATment of ATopic Eczema (TREAT) Registry Taskforce: An initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries. J Invest Dermatol. 2017; 137: 2014-2016. CrossRef PubMed

[20] Busch M, Maske U, Ry L, Schlack R, Hapke U. [Prevalence of depressive symptoms and diagnosed depression among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013; 56: 733-739. CrossRef PubMed

[21] Thyssen JP, Hamann CR, Linneberg A, Danoff BM, Skov L, Gislason GH, Wu JJ, Egeberg A. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy. 2018; 73: 214-220. CrossRef PubMed

[22] Andersen YM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol. 2017; 76: 274-280.e1. CrossRef PubMed

[23] Eckert I, Gupta S, Gudkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019; 81: 187-195. CrossRef PubMed

[24] Redaktion Facharztmagazin. EU-Kommission erteilt Neuzulassung für JAK-Inhibitor. ästhetische dermatologie & kosmetologie. 2020; 12; 48.

[25] Reich K, Kabashima K, Peris K, Silverberg JJ, Eichenfield LF, Bieber T, Kaszuba A, Kolodwick J, Yang FE, Gamol M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020; 156: 1333-1343. CrossRef PubMed

[26] Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JJ, Bieber T, Kabashima K, Tsnemi Y, Costanzo A, Gutman-Yassky E, Beck LA, Jones...
Siegels, Haufe, Heinrich, et al. 286

JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020; 183: 242-255. CrossRef PubMed

Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, Hijnen D, Jensen TN, Bang B, Olsen CK, Kurkbasic A, Weidinger S; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021; 184: 450-463. CrossRef PubMed

Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Sueki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, et al; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021; 184: 437-449. CrossRef PubMed

Redaktion Facharzt Magazine. Neue Daten zu JAK-Inhibitor. ästhetische dermatologie & kosmetologie. 2020; 12: 46.

Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Papp KA, Reich K, Beck LA, Mohamed MF, Othman AA, Anderson JK, Gu Y, Teixeira ID, Silverberg JI. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020; 145: 877-884. CrossRef PubMed